Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,297 across all filing types
Latest filing 2024-08-08 Regulatory Filings
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a new contract worth USD 156.8 million received by Bavarian Nordic from BARDA (U.S. government) for the production of JYNNEOS® vaccines. It provides key financial updates related to this contract and reiterates the company's full-year financial guidance. This format—a brief, immediate announcement of a significant event (a new contract/order) that impacts financial outlook, often released outside of standard quarterly reporting cycles—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is an initial announcement of a major financial event (a new contract award) rather than a full financial report (like 10-K or IR), and it is not a transcript (CT) or a proxy statement (DEF 14A), the most fitting category is Earnings Release (ER), as it immediately communicates key financial performance drivers and guidance updates. It is not a Report Publication Announcement (RPA) because it contains the substance of the news, not just a notice that a report is available.
2024-08-08 Danish
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
Regulatory Filings Classification · 98% confidence The document is a corporate announcement from Bavarian Nordic regarding a new contract with the U.S. government (BARDA) for vaccine production. While it contains financial details and forward-looking statements, it is primarily a press release announcing a specific business development (a new contract). It concludes with a 'Company Announcement' number and a link to an attached file, which aligns with the definition of a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of the announcement regarding a contract award, it fits best as a regulatory filing/announcement.
2024-08-08 Danish
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
Regulatory Filings Classification · 95% confidence The document is a press release from Bavarian Nordic announcing a new contract with the U.S. government for vaccine production. While it mentions financial guidance, it is primarily an announcement of a specific business development/contract win. The document explicitly labels itself as 'Company Announcement no. 21 / 2024' and includes an 'Attachment' link, which aligns with the definition of a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of the announcement regarding a contract award, it fits best as a Regulatory Filing (RNS) as it serves as a formal corporate disclosure.
2024-08-08 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a press release from Bavarian Nordic announcing that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for their Chikungunya vaccine candidate (CHIKV VLP). This announcement details regulatory progress (filing acceptance, accelerated assessment) and provides context on the vaccine and the disease. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Audit Report (AR). It is a specific corporate update regarding regulatory milestones. Since it is an announcement about a regulatory submission/acceptance, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad regulatory update that doesn't fit the more specific categories like Director's Dealing (DIRS) or Capital Change (CAP). Given the nature of the announcement (regulatory progress), RNS is the most appropriate general regulatory category.
2024-07-18 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a press release dated July 18, 2024, announcing that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Bavarian Nordic's chikungunya vaccine candidate (CHIKV VLP). It details the regulatory process (accelerated assessment, centralized procedure) and mentions the submission to the FDA. This type of announcement, which communicates a significant regulatory milestone or event rather than providing full periodic financial results (like 10-K or IR) or a transcript (CT), typically falls under general regulatory announcements or investor news. Since it is a specific announcement about regulatory progress and not a general filing like a 10-K or an earnings release (ER), and it doesn't fit other specific categories like DIRS, DIV, or MANG, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such corporate news releases that don't fit elsewhere, or potentially a Capital/Financing Update (CAP) if the news implies future revenue, but RNS is safer for general regulatory updates. Given the content is purely about regulatory validation and next steps, RNS is the best fit as a general regulatory announcement.
2024-07-18 Danish
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Bavarian Nordic regarding the EMA's validation of a registration application for a chikungunya vaccine. It is a regulatory announcement detailing a specific business development milestone. Since it does not fit into specific categories like financial reports, board changes, or dividend notices, and serves as a general regulatory update, it is classified as an RNS (Regulatory Filing).
2024-07-18 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.